See All Slides - tctmd.com

Slides

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

Presentation AHA 2016

Arterial Revascularization Trial (ART)

Presenter: David P. Taggart

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

Presentation AHA 2016

FUnctional Testing Underlying REvascularization: The FUTURE trial

Presenter: Gilles Rioufol

November 15, 2016

Presentation Cardiovascular Interventions 2016

Precision PCI

Presenter: Richard Shlofmitz

November 11, 2016

Presentation Cardiovascular Interventions 2016

It's Not All About the Epicardial Vessel... Pay Attention to the Microvasculature!

Presenter: Bruce Samuels

November 11, 2016

Presentation Cardiovascular Interventions 2016

What's Wrong with MOC and re-certification?

Presenter: Paul S. Teirstein

November 11, 2016

Presentation Cardiovascular Interventions 2016

Unprotected Left Main Stenting

Presenter: Paul S. Teirstein

November 10, 2016

Advertisement

Slides

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Arterial Revascularization Trial (ART)

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

FUnctional Testing Underlying REvascularization: The FUTURE trial

Precision PCI

It's Not All About the Epicardial Vessel... Pay Attention to the Microvasculature!

What's Wrong with MOC and re-certification?

Unprotected Left Main Stenting

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content